Advanced Filters
noise
Found 57,567 clinical trials
G Gustavo Akerman Augusto, MD

Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

This is a Phase III Randomized Clinical Trial, blind, multicenter, with active controls, to evaluate the immunogenicity and safety of the Quadrivalent Influenza Vaccine (split virion, inactivated) from Instituto Butantan, in two dose scheme (0.25ml and 0.50ml), in infants and children under 3 years of age.

6 - 35 years of age Both Phase 3
X Xiuwu Hu, Dr

Effect of Korean Red Ginseng on Oxidation in Middle-aged and Elderly Sub-health Population

The objective of this study is to examine the effects and safety of Korean red ginseng capsule and placebo with middle-aged and elderly sub-health population.

40 - 75 years of age Both Phase 2/3
A Ariana Kamberi

Adapt2Quit - An Adaptive Motivational System for Socio-Economically Disadvantaged Smokers

The goal of this research is to test the Adapt2Quit computer program that uses participant input (message rating on how much the text motivational message might influence one to quit smoking) to select and text motivational messages that are more likely to help a user stop smoking. This Adapt2Quit system …

18 - 99 years of age Both Phase N/A
Q Qiang Liu

Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population

This is a randomized, double-blind, positive controlled design clinical trial of tetanus vaccine, adsorbed manufactured by Sinovac Life Sciences Co., Ltd.The purpose of this study is to evaluate the safety and immunogenicity of tetanus vaccine, adsorbed in 18~44 years old population.

18 - 44 years of age Both Phase 3
J Jules Alonga, MD

Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC

The goal of this observational study is to monitor and assess the safety profile of the MVA-BN vaccine among staff and study personnel of the PALM-007 study in the Democratic Republic of the Congo. The main questions it aims to answer are: To estimate the incidence of serious adverse events …

18 - 100 years of age Both Phase 4
A Alban LE MONNIER, MD, PhD

Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile

Data on the seroprevalence of antibodies to Clostridioides difficile surface proteins and toxins are scarce. In 1983, Viscidi et al. showed that antibodies to C. difficile toxins A and B were detected in 60 to 70% of an adult population. Two-thirds of the adults tested had a serological trace, probably …

18 - 100 years of age Both Phase N/A
D Demetrius Lopes, MD

Envi™-SR Randomized Controlled Trial for Endovascular Treatment of Ischemic Stroke

The study objective is to examine and compare clinical outcomes, as measured by Modified Rankin Scale (mRS) at 90 days (± 15 days) post treatment, and related performance characteristics of the Envi™-SR and concurrent parallel Control Devices currently cleared by the U.S. FDA for treatment of stroke.

18 - 100 years of age Both Phase N/A
S Suzanne Rataj, MPH

Promoting Community Conversations About Research to End Native Youth Suicide in Rural Alaska

This intervention study measures the outcomes of the PC CARES (Promoting Community Conversations about Research to End Suicide) project implemented in remote rural Alaskan villages. Researchers worked with local service providers and other partners to recruit facilitators who were trained to implement the 5-session PC CARES curriculum. The study will …

15 - 100 years of age Both Phase N/A

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation …

18 - 100 years of age Both Phase 3
E Elizabeth S. Haag, RN

Optical Coherence Tomography of the Saphenous Vein Graft

OCTOCAB is a prospective, randomized (1:1), single-center trial. The purpose of this study is to determine whether intravascular optical coherence tomography (OCT) guided saphenous vein grafting in coronary artery bypass surgery will reduce the rate of early vein graft failure (VGF).

18 - 100 years of age Both Phase N/A

Rewrite in simple language using AI